Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer

BACKGROUND: Cisplatin is a first-line drug for the treatment of human non-small cell lung cancer (NSCLC); however, the majority of patients will develop drug resistance after treatment. In order to overcome cisplatin resistance, it is important to understand the mechanisms underlying the resistance....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer
Hlavní autoři: Wang, Wenjing, Zhao, Mengyue, Cui, Lijuan, Ren, Yong, Zhang, Jingyuan, Chen, Junli, Jia, Lina, Zhang, Jiayu, Yang, Jingyu, Chen, Guoliang, Ashby, Charles R., Wu, Chunfu, Chen, Zhe-Sheng, Wang, Lihui
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7466461/
https://ncbi.nlm.nih.gov/pubmed/32878625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-020-01256-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky